Stock Alerts
Adding Independent Bank to my Dividend Portfolio
Just in case you haven't noticed, it's really, really hard at the moment to find a decent dividend yield in a stock that doesn't require taking on substantial risk. That's what happens when you've got elevated asset prices after a long rally, a still-low interest rate...
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Leveraging near-term Incyte catalysts by adding call options to Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Holding Incyte in my Jubak Picks portfolio for mid-year catalysts
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out--results from critical drug trials weren't likely to be reported for two years. The reason to hold onto...
Selling Acadia Pharmaceuticals out of my Jubak Picks portfolio
Today I'm selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective for...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
Selling Caterpillar on the President’s tariff announcement
I don't think there's any point to waiting around to see how quickly or fiercely China (and the European Union) will retaliate against U.S. exporters after today's announcement that the United States will put a 25% tariff on Chinese (and other imported) steel and a...
Selling Boeing shares on the President’s tariff announcement
I don't think there's any point to waiting around to see how quickly or fiercely China (and the European Union) will retaliate against U.S. exporters after today's announcement that the United States will put a 25% tariff on Chinese (and other imported) steel and a...Adding Pioneer Natural Resources call options for January 18, 2019 at $180 to my Volatility Portfolio
I'm adding call options in a Permian Basin oil shale producer, Pioneer Natural Resources (PXD). I think the oil market is a good candidate for disruption in 2018 either from OPEC's efforts to drive the price of oil above $70 or from an outbreak of conflict in the...
Selling MGM March 16 calls out of my Volatility Portfolio
Shares of MGM Resorts International (MGM) rose 2.52% on Friday, February 23, to close at $35.38. I'm going to use that move to the upside to sell my March 16, 2018 MGM calls (MGM180316C00033000) out of my Volatility Portfolio. I bought these options back on September...
Buying call Nektar options at $90 for August 17, 2018 expiration in my Volatility Portfolio
When I started my rebalancing of my Volatility Portfolio on February 20, I thought I would add the slightly in the money Nektar Therapeutics (NKTR) calls at $80 with an expiration of August 17, 2018 at a closing price of $18.50. But the underlying stock has moved up...Jim’s Stock Alerts
Download Jim’s eBook for Free
